In the TME, approaches such as immune checkpoint inhibition (e.g., PD-L1 inhibitors), immune cell modification (e.g., CAR-T, CAR-NK, and CIK cells), and cytokine regulation (e.g., VEGF inhibitors) can improve the TME, enhance immune function, and inhibit tumor progression. This evidence concerns the gene VEGFA and neoplasm.